Pharmaceutical Executive-08-01-2016

As market headwinds persist, our latest industry review of shareholder value reveals a sharp performance differential between companies that pursue a strategy of specialized therapeutic focus and those that continue to rely on line diversity, size and scale.

With our annual Industry Audit marking its 15th year, we decided to compare 2002 approaches in boosting shareholder value to those of today. The fall in one particular performance metric is telling.

Pharm Exec convenes some of the industry’s top business development professionals and negotiators to talk about the current climate for biophamara dealmaking and the critical job of appraising new assets and their potential as market-worthy and transformative products for patients.

Pharm Exec sits down with AmerisourceBergen supply chain leader Peyton Howell to discuss the latest trends in pharmaceutical distribution, including company efforts to boost efficiency, reliability, and enhance its groundbreaking partnership with Walgreens Boots Alliance.

Analysts examine investment and business factors that shape supply disruptions.

Balancing today’s health data demands and patient privacy is not about new regulations-it’s taking a risk-based approach.

A look at the EU plans for a European patent, and where the UK fits in the mix.

The chances are slim, but a new resolution in Europe on the subject could drum up support for a Brexit-like scenario.

Although Hungary has posted the third-highest economic growth rate in the EU since 2014, its healthcare system is struggling-dictating the need for new efforts if the country is to regain its dominance as a central and eastern European-region trailblazer in the life sciences.

Click the title above to open the Pharmaceutical Executive August 2016 issue in an interactive PDF format.